



Responses to Reviewers

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 23001

Title: A rare case of Sclerosing Mesenteritis and Low Grade Follicular Lymphoma.

Reviewer's code: 00462645

Reviewer's country: France

Science editor: Fang-Fang Ji

Date sent for review: 2015-10-14 14:47

Date reviewed: 2015-10-14 17:55

In this study the authors report a case of a man with a metabolic syndrome story. The patient got a dual treatment with glucocorticoid and tamoxifen which evolved through a lymphoma. This case study is interesting and deserve publication I suggest the authors open the discussion citing supplementary references related to the importance of sterol metabolism as tamoxifen alternative mechanism of action that could explain these side effects (see for example Silvente-Poirot et al, Science, 2014)

Author's Response:

Thank you for your review and valuable comments. We do note your comment about alternative sterol's metabolism in carcinogenic pathways. Cancer has been associated with cholesterol, as it is the obligatory precursor of steroid hormones that are involved in tumour promotion (estrogens, androgens) as well as tumour death (glucocorticoids). Science 343(6178):1445-6 · March 2014.

Studies have indicated increased risks of malignant lymphomas among individuals treated with corticosteroids, but have not taken into account the underlying reasons for steroid use, so the increased risks might be attributable to the underlying disease or concomitant treatments other than steroids. Askling et al addressed this in 2005 and concluded that even at considerable cumulative doses; steroids may not appreciably increase lymphoma risk.

Do steroids increase lymphoma risk? A case–control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis

[J Askling](#), [L Klareskog](#), [H Hjalgrim](#), [E Baecklund](#), [M Bjorkholm](#), and [A Ekbom](#)

Ann Rheum Dis. 2005 Dec; 64(12): 1765–1768.

Tamoxifen is a nonsteroidal triphenylethylene based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. A number of second primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.

In the largest series of 92 cases of Sclerosing Mesenteritis from Mayo clinic by Akram et al looking at clinical features, treatment and outcome, the median length of follow up was 20.5 months. They found 3 patients with concurrent intraabdominal Non Hodgkin's Lymphoma and 3 women with ovarian tumors. One case of B-cell Lymphoma was found 5 years after the diagnosis. They proposed that this was related to monoclonal or oligoclonal B- cell expansion that is observed in other fibrotic processes such as retroperitoneal fibrosis. [5]

In this case we propose that it was the underlying fibrotic and inflammatory process that resulted in transformation into a lymphoma



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 23001

Title: A rare case of Sclerosing Mesenteritis and Low Grade Follicular Lymphoma.

Reviewer's code: 00504611

Reviewer's country: United Kingdom

Science editor: Fang-Fang Ji

Date sent for review: 2015-10-14 14:47

Date reviewed: 2015-10-22 22:35

This is an interesting case report. 1. In all the Figures, it would be helpful to indicate with arrows the features being referred to. 2. Minor typos eg laparotomy, positeron, etc require correction.

Author's Response:

Thanks for appreciating the case report and valuable suggestions. As per your suggestion I have marked the relevant features with arrows on relevant figures and corrected the minor typing errors as pointed.

Answer to chief editor:

Hi Fang-Fang Ji

We have made a few changes as well as seemed appropriate , otherwise it is all looking ok with a correction in conflict of interest section.

Best regards

Seema